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C
oronary artery calcium (CAC) scanning is one of the most powerful novel tests to improve cardiovascular (CV) risk assessment. Numerous prospective studies have demonstrated significant improvement in discrimination of CV events and enhanced clinical risk reclassification when CAC testing is added to traditional risk factors for CV disease.
1-3 CAC scanning may also improve the efficiency and appropriateness of statins and aspirin allocation for primary prevention. 4, 5 A cornerstone of the new 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines is the primacy of informed decision making regarding statin use through the physician-patient discussion. 6 Although CAC scanning holds significant promise for assessing CV risk and informing individual patient decisions, the optimal method of integrating CAC data with other risk factor data are unclear.
A common method of incorporating CAC results is to use fixed values or thresholds, such as a CAC score of 0 or >300, to downgrade or upgrade CV risk, respectively. 7 Although this is a clinically simple approach, it ignores the spectrum of risk along gradations of both CAC scores and risk factor levels. In fact, even among those with CAC=0, CV risk varies widely depending on the severity of risk factors. 5 An alternate approach is to integrate actual CAC scores and risk factor data into a combined risk calculator to provide a more accurate actuarial assessment of CV risk. Recently, the MESA investigators (Multi-Ethnic Study of Atherosclerosis) developed the first such integrated CAC calculator to predict coronary heart disease (CHD) risk, which was validated in 2 external cohorts. 8 This calculator, which was derived in a predominantly older cohort (45-85 years; mean, 65 years), offers much clinical utility and is already being applied to enhance the clinician-patient risk discussion. High-resolution risk assessment can also be critical in younger populations of individuals, in particular, those in high-risk occupations. Indeed, this study was stimulated by the National Aeronautics and Space Administration to enhance CV risk prediction for the astronaut population who are predominantly middle-aged men and women. The MESA CHD calculator also did not assess the broader ASCVD end point, which includes stroke and which is the focus of the 2013 ACC/AHA Cholesterol and Risk Guidelines. 6, 7 There is currently no such integrated CAC and risk factor calculator available to determine the risk of ASCVD.
Thus, using data from 3 large, population-based cohorts with risk factor, CAC, and event information, we sought to develop an integrated risk factor and CAC calculator for younger individuals in the general population (40-65 years) to estimate the risk of ASCVD. The tool, termed the Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) calculator, was assessed for validity in a fourth cohort, the FHS (Framingham Heart Study).
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure; however, the MESA and FHS study data are publicly accessible, and we encourage parties interested in collaboration and data sharing to contact the corresponding author directly for further discussions.
Study Populations
Data were pooled from study participants from examination 1 of MESA, phase 1 of the Dallas Heart Study (DHS), and the PACC study (Prospective Army Coronary Calcium Project) for the derivation cohort. The model validation cohort derived from the FHS Offspring and Third Generation cohorts. The development of the Astro-CHARM model was supported by the National Space Biomedical Research Institute to create an ASCVD risk assessment tool for astronauts, who undergo routine CAC screening, and a tool that can be used for the general population, as well. As such, these studies were selected because they comprised US population-based cohorts that included CAC scanning and ASCVD outcomes data, and that spanned middle-aged individuals (ie, 40-65 years). The study designs for MESA, 9 the DHS, 10 PACC, 11, 12 and the FHS cohorts 1, 13 have been previously described, and a detailed description of cohort methods and included participants are provided in the online-only Data Supplement and Figure I in the online-only Data Supplement. Each separate study was approved by the respective local institutional review boards, and all participants gave written informed consent for participation in those studies as described in the online-only Data Supplement. The overall Astro-CHARM study protocol was
Clinical Perspective
What Is New?
• Coronary artery calcium is among the most powerful novel cardiovascular risk assessment tests, but there previously was no available tool to combine coronary artery calcium and traditional risk factor information.
• ) , a latex-enhanced immunoturbidimetric method; PACC, particleenhanced immunoturbidimetric latex agglutination assay; FHS, enhanced immune turbidimetric high-sensitivity assay (Roche Diagnostics). In the PACC study, hs-CRP measures were not performed in 907 subjects; these values were imputed as described in the online-only Data Supplement.
CAC Assessment
For all studies, CAC scores were quantified by using standard Agatston unit methodology. 14 Detailed methods for CAC scanning in each study are provided in the online-only Data Supplement and Table I in the online-only Data Supplement. In brief, CAC was measured by electron-beam computed tomography in 3 MESA sites, in DHS, and in PACC, and by multidector computed tomography in 3 other MESA sites and in the FHS.
Clinical End Point Ascertainment and Definition
The primary end point for the study included a composite of nonfatal MI, nonfatal stroke, or death from CHD or stroke. The components of this end point were available for MESA, DHS, and FHS, but only nonfatal MI and CVD death were available for PACC. Few nonfatal stroke events would have been anticipated in this younger, generally healthy cohort with a low prevalence of hypertension, and fatal stroke is included in the CVD death end point. Data acquisition methods, end point adjudication, and primary end point components for each individual study are described in the online-only Data Supplement and Table I in the online-only Data Supplement.
Statistical Methods
Individual participant level data from MESA, DHS, and PACC were combined for model derivation. Associations of risk factors with study outcomes were assessed by using Cox proportional hazards models. The baseline risk factor model comprised those variables included in the ACC/AHA Pooled Cohorts Equation (PCE) 7 : age, sex, race/ethnicity (white, black, Hispanic, other), total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, hypertension medication use, current smoking, and diabetes mellitus. β-Coefficients for these variables were fit to the derivation set and were not those from the original PCE, and all components of the PCE were intentionally retained in the model regardless of statistical significance. The Astro-CHARM model was constructed by then adding CAC scores as ln (CAC+1) given the skewed distribution. Next, family history of MI, hs-CRP, statin use, and fasting glucose levels were added based on a priori determination of their potential to improve the model. 3, 8, 15 Only family history of MI and hs-CRP were independently associated with ASCVD events and were included in the full Astro-CHARM model. Nonlinear relationships were explored by assessing exponential terms for age, and interactions were also assessed between CAC and age, sex, or race (no statistically significant interactions found). Assumptions for the Cox proportional hazards models were verified by Schoenfeld residuals. Weibull models were also evaluated, but β-coefficients were similar to those determined using Cox models.
Discrimination was assessed using the Harrell c-statistic, with 95% CIs determined by a jackknife resampling method. Improvement in the c-statistic was determined by using bootstrap resampling. Integrated discrimination improvement, reflecting the difference in discrimination slopes between models with and without the markers, was determined using the failure probabilities from the Cox proportional hazards models. Categorical net reclassification improvement (NRI) was performed according to methods of Pencina et al 16 by cross-tabulating the risk factor model with the Astro-CHARM model, using predicted risk categories of <5%, 5 to <7.5%, and ≥7.5% 10-year ASCVD risk. Separate analyses were performed for events and nonevents, and 95% CIs were calculated using bootstrapping. Calibration of the Astro-CHARM model was assessed by the Nam D'Agostino χ 2 test for time-to-event data. Bootstrapping was used in determining the β-coefficients for the Astro-CHARM model. 17 Bootstrapping has the advantage that the entire data set is used for model development, as opposed to cross-validation techniques. In particular, 1000 model fits were created, and the average β-coefficient was determined across all these iterations. The β-coefficients were optimized by calculating the optimism in the β-coefficients and averaging the optimism estimates to arrive at the overall β-coefficient optimism values. The bootstrap-corrected β-coefficients were calculated; this is an honest estimate of internal validity of the β-coefficients. The coefficients were then applied to the FHS cohort where model discrimination was assessed using the Harrell c-statistic. Calibration plots were constructed and calibration was assessed using the Nam D'Agostino χ 2 test. Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Inc), and all P values are 2-sided with an α of 0.05.
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RESULTS
The baseline characteristics of the derivation and validation study cohorts are provided in Table 1 . The mean age of the pooled derivation overall cohort was 51.0 years (SD ±7.5), 55% were men, and 30% were black with some heterogeneity among individual study cohorts. Among the pooled derivation cohort, the median CAC score was 0 (25th, 75th percentiles [0, 9]). The proportions of individuals with CAC scores of 0, 1 to 99, 100 to 399, and ≥400 were 63%, 27%, 7%, and 3%, respectively. Over a median of 10.9 years, 304 hard ASCVD events occurred. When added to the baseline risk factor model including all PCE components, CAC, family history of MI, and hs-CRP all remained significantly associated with incident ASCVD and comprised the full Astro-CHARM model, whereas fasting glucose and statin use were not associated ( Table 2 ). The c-statistics for the risk factor model, CAC model, risk factor model+CAC, and full Astro-CHARM model were 0.784, 0.720, 0.813 (P=0.0002), and 0.817 (P≤0.0001 versus risk factor model), respectively ( Figure 1 ). The Astro-CHARM model was superior for prediction of MI (cstatistic risk factor model without recalibration=0.743, Astro-CHARM=0.827) versus stroke (risk factor model without recalibration=0.778, Astro-CHARM=0.781), although the model β-coefficients were optimized for the composite ASCVD end points rather than fit for each end point separately.
In comparison with the risk factor model, the full Astro-CHARM model resulted in a significant categorical NRI of 0.121, P<0.0001 (Figure 2) , and integrated discrimination improvement of 0.0252 (0.0157-0.0346). The overall significant NRI result was driven by a 12% appropriate upclassification of risk, with no statistical difference in appropriate downclassification. In sensitivity analyses expanding the intermediate risk group to 5% to 15% 10-year risk, the performance of the Astro-CHARM model was enhanced with a categorical NRI of 0.141, P<0.0001 ( Figure II A modified Astro-CHARM model without hs-CRP was also constructed that demonstrated good discrimination (c-statistic, 0.826) and calibration, and a significant categorical NRI and integrated discrimination improvement (Tables II and III in 
Model Validation
The mean age of the FHS cohort (n=2052) was 49.6 years (±6.7), with 49% men and 100% white individuals ( Table 1 ). The median follow-up for the cohort was 9.5 years, and a total of 55 hard ASCVD events oc- 
Mobile Application and Web-Based Tool
To facilitate clinical application of the Astro-CHARM CAC risk calculator, a mobile application ( Figure VI in the online-only Data Supplement) was developed, and a web-based tool (www.Astro-CHARM.org) ( Figure VII in the online-only Data Supplement). Both instruments provide an estimated 10-year risk of ASCVD based on Astro-CHARM parameters including those from the PCE risk score, and the CAC score and family history of MI, with or without hs-CRP measures, as well.
DISCUSSION
In the present study, we provide the first integrated CAC and risk factor calculator that estimates the 10-year risk of ASCVD events. The Astro-CHARM calculator was developed using 3 large, population-based cohorts, 2 of which involved multiethnic populations, enhancing generalizability. We validated the Astro-CHARM tool in a fourth population-based cohort where it demonstrated very good discrimination and calibration. The Astro-CHARM can be a valuable tool for ASCVD risk assessment in younger individuals in the general population.
In clinical medicine, risk assessment is at the center of CV disease prevention strategies. Determining an individual's absolute risk allows calculation of the absolute risk reduction and number needed to treat for any preventive strategy, thus providing quantitative measures of potential benefits. Current recommendations for aspirin and statin use are based on 10-year ASCVD thresholds (>10% and >7.5%, respectively), weighing the potential benefits against potential harms of each therapy. 6, 18 Indeed, there is increased interest in not only providing more accurate risk estimates, but also in enhanced communication of risk to patients to better inform their involvement in treatment strategies. 19 These objectives are core components of the National Institute of Health Precision Medicine Initiative All of Us Research Program that seeks to identify prevention and treatment strategies that take individual variability into account, to individualize medical treatments and decision making to the patient. 20 Of all the emerging risk indicators, CAC scanning has demonstrated the most substantial impact on enhancing CV risk estimates and the most robust evidence base to support its use.
1-3 Nevertheless, there remains hetero- *Hazard ratio per 1 SD unit of continuous predictor variable; SD for age=7.5; total cholesterol=37.5; high-density lipoprotein cholesterol=14.7; systolic blood pressure=17.5; high-sensitivity C-reactive protein=4.8; and coronary artery calcium score, natural log=1.95.
Astro-CHARM indicates Astronaut Cardiovascular Health and Risk Modification.
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geneity in the recommendations for its clinical use. The ACC/AHA 2013 Cholesterol Guidelines stated that, if there is uncertainty regarding statin use after quantitative risk assessment, a coronary calcium score ≥300 or ≥75th percentile may be used to upgrade risk. Others have advocated for an alternate strategy of using CAC to downgrade risk for scores of 0. 21 Both approaches exchange simplicity for precision and may lead to erroneous risk-based decision making. For example, in the Heinz Nixdorf Recall study, among all individuals with a CAC score >400, observed 5-year CHD events varied markedly based on risk factor clustering, ranging from 3.5% in those at low Framingham Risk Score estimated 10-year CHD risk to 10.6% for those at high estimated Framingham Risk Score risk. 22 Similarly, in the MESA study, subjects with a CAC score of 0 had a 10-year ASCVD event rate of ≈2.7% if they were also in an estimated ASCVD risk category of 7.5% to 9.9% in comparison with ≈12% event rate if they were in an estimated risk category of >20%. 5 Both the Heinz Nixdorf and MESA data suggest that using simplified CAC thresholds may ignore valuable information that can impact risk-based decisions.
Recently, McClelland et al 8 developed an integrated risk factor and CAC calculator using the MESA study cohort. This tool estimates the 10-year risk of CHD, inclusive of coronary revascularization, and was validated in 2 external cohorts. In the current study, we developed a CAC risk calculator from 3 different cohorts to estimate the risk of hard ASCVD (MI, stroke, CHD death, stroke death) in accordance with the 2013 ACC/AHA Cholesterol and Risk Assessment Guidelines. 6, 7 This Astro-CHARM tool also focuses on a younger population (40-65 years; mean age, 51 years), in comparison with the MESA CHD calculator derived from an older population (45-85 years; mean age, 65 years). Given the dominance of age in risk assessment, most older individuals are already eligible for statins, and CAC risk calculators may have differing applications for younger populations, especially in those working in high-risk occupations like astronauts. Indeed, the main impact of Astro-CHARM was to appropriately upclassify clinical risk category (ie, statin eligibility), whereas CAC scanning is commonly used to downgrade risk and statin eligibility in older individuals with CAC of zero. 23 Our findings validate recent observations from both MESA and FHS that CAC measures can enhance risk assessment of ASCVD events. 1, 3 In addition, both family history of MI and hs-CRP measures also remained independently predictive of ASCVD beyond CAC values, and were incorporated in the full Astro-CHARM model. Prior studies have demonstrated the additive value of family history of MI and CAC, in particular, in younger populations. 24 Given that hs-CRP is not always obtained in clinical practice, an additional model excluding hs-CRP was provided. It is interesting to note that statin use was not predictive of ASCVD events when added to the Astro-CHARM model. This may signify that CAC The areas under the receiver operating curves for prediction of atherosclerotic cardiovascular disease (ASCVD) events are presented for the Astro-CHARM and risk factor-only models, with significant improvement using Astro-CHARM (P=0.0003). and lipid values encompass the predictive information provided by statin prescription. In the MESA CHD calculator, lipid-lowering medication use was also not statistically associated with CHD events but was nominally associated with increased risk among those taking these medications. The Astro-CHARM model is best applied to individuals not already on statins for risk-based decisions given the complexity of ascertaining treatment effects in observational data sets, and because such individuals comprise >90% of the Astro-CHARM data set.
The present study has several strengths including derivation and validation using 4 large study cohorts. However, several limitations should be acknowledged. First, the PACC study had shorter follow-up and few ASCVD end points, and CRP values were imputed for ≈50% of this study cohort. However, the risk estimates derived after excluding the PACC cohort were nearly indistinguishable and the Astro-CHARM model without CRP was also well-calibrated. In addition, the Framingham validation cohort had a modest number of ASCVD events. Unfortunately, there are few US population-based studies with CAC and fatal/nonfatal end point data to contribute to validation beyond the 3 cohorts used in model derivation. Nevertheless, the Astro-CHARM demonstrated good discrimination and calibration in this cohort, and the number of events is comparable to validation cohorts for other contemporary widely applied risk scores.
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Conclusions
The Astro-CHARM is the first integrated CAC and risk factor calculator for the prediction of ASCVD. It has improved discrimination and net clinical reclassification in comparison with the pooled cohort equations risk factors, and is well calibrated for 10-year ASCVD event estimation. Its development and validation involving 4 population-based cohorts enhances its generalizability for clinical practice. It may be a valuable tool for risk assessment and in risk-based decision making for CV disease prevention in the general middle-aged population.
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